A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies

To determine the therapeutic efficacy (13-week and 26-week CNS progression-free survival [PFS], response rate, and overall survival) and safety of intraventricular (IVent) topotecan in patients with neoplastic meningitis (NM), we conducted a phase II, open-label, nonrandomized, single-arm trial of I...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Groves, Morris D., Glantz, Michael J., Chamberlain, Marc C., Baumgartner, Karen E., Conrad, Charles A., Hsu, Sigmund, Wefel, Jeffrey S., Gilbert, Mark R., Ictech, Sandra, Hunter, Kathy U., Forman, Arthur D., Puduvalli, Vinay K., Colman, Howard, Hess, Kenneth R., Yung, W.K. Alfred
Formato: Artigo
Lenguaje:Inglês
Publicado: Duke University Press 2008
Materias:
Clinical Investigations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2613823/
https://ncbi.nlm.nih.gov/pubmed/18316473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2007-059
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Cargando...

Ejemplares similares